Semax
MetabolicFor metabolic-syndrome, type-2-diabetes-spectrum, and obesity-medicine indications, Semax is one component in a multi-layer protocol. Elevates BDNF and NGF in hippocampus and cortex Modulates dopamine and serotonin transporter expression. Inhibits enkephalinase, indirectly extending endogenous enkephalin action. Approved in Russia for stroke rehabilitation and cognitive disorders.. CGM-tracked individual response in the first cycle, paired with adequate protein intake and resistance training, is the practical framework for evaluating whether Semax contributes meaningfully at the 300-2000 mcg per dose (varies) 2-4x daily for 10-14 day courses dose.
Key Takeaways
Metabolic lens: Semax is tracked against glycemic, insulin sensitivity, visceral adiposity, and inflammatory markers. Mechanism: Elevates BDNF and NGF in hippocampus and cortex. Metabolic monitoring: baseline HbA1c, fasting glucose, fasting insulin, HOMA-IR, hsCRP, ALT/AST; ideally CGM in first cycle. Metabolic dose: 300-2000 mcg per dose (varies) 2-4x daily for 10-14 day courses via intranasal. Metabolic-medicine stack partners: Semaglutide (GLP-1), Cagrilintide, MOTS-c.
Elevates BDNF and NGF in hippocampus and cortex. Modulates dopamine and serotonin transporter expression. Inhibits enkephalinase, indirectly extending endogenous enkephalin action. Approved in Russia for stroke rehabilitation and cognitive disorders. Metabolic implications: how the mechanism interacts with insulin signalling, AMPK and mitochondrial biogenesis, visceral adiposity, and the appetite circuit. Semax's contribution at each layer is examined in the subsections below, with reference to the clinical biomarkers (HbA1c, fasting insulin, HOMA-IR, hsCRP, ALT/AST) that track each.
Insulin signalling and glycemic effect
Semax's relationship to insulin signalling is one of the central practical considerations. Direct incretin-axis effects are limited, but downstream insulin sensitivity is influenced through inflammatory, mitochondrial, or weight-related mechanisms. The implication for glycemic monitoring is clear: baseline HbA1c, fasting glucose, and — ideally — a CGM during the first cycle for users in or near the diabetes-spectrum range.
AMPK and mitochondrial signalling
Independent of insulin-receptor pharmacology, several peptides in this category engage AMPK and mitochondrial biogenesis pathways. Semax engages this layer indirectly through its effect on adiposity, inflammation, and the broader metabolic milieu. The practical effect is sustained shifts in fasting insulin, fasting glucose, and energy expenditure that are not visible in single-meal glycemic curves but accumulate across a cycle.
Visceral fat and the cardiometabolic axis
Semax's effect on visceral adipose tissue, hepatic steatosis, and cardiometabolic risk indices is the dimension most clinically tracked. Visceral adipose effects emerge gradually over months of consistent dosing rather than acutely. The most-tracked markers are waist circumference, ALT/AST (hepatic), hsCRP (inflammation), and — where available — DEXA-quantified visceral fat.
Where Semax is used for liver metabolism, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
Semax for weight management is best-evaluated against baseline metabolic markers: fasting glucose, HbA1c, lipid panel, hsCRP, ALT/AST. Response timelines are typically 8–12 weeks for primary endpoints; secondary markers (inflammation, hepatic function) move on similar timescales.
In the metabolic syndrome population, Semax for cardiometabolic risk produces measurable shifts on the cardiometabolic axis when paired with appropriate dietary and activity inputs. The compound's effect is additive to lifestyle rather than substitutive for it.
Where Semax is used for appetite regulation, integration with GLP-1 agonist therapy, AMPK activators, or visceral-fat-selective agents is the standard pattern in metabolic medicine clinics. Mono-therapy is appropriate for first-cycle users and for milder presentations.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | Intranasal | 300-2000 mcg per dose (varies) | 8–12 weeks on / 4 weeks off |
| Conservative starter | Intranasal | 180-2000 mcg per dose (varies) | 4–6 weeks initial cycle |
| Metabolic focus | Intranasal | 300-2000 mcg per dose (varies) | 2-4x daily for 10-14 day courses |
| Maintenance phase | Intranasal | 210-2000 mcg per dose (varies) | Ongoing with periodic pauses |
Dose timing for Semax is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Semax stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from metabolic medicine specialists.
- Semax + Semaglutide (GLP-1): Selective GLP-1 receptor agonist. Pairs naturally with Semax's mechanism in metabolic / endocrine protocols.
- Semax + Cagrilintide: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Pairs naturally with Semax's mechanism in metabolic / endocrine protocols.
- Semax + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Semax's mechanism in metabolic / endocrine protocols.
- Semax + Tesamorelin: Modified GHRH (1-44) sequence with an N-terminal trans-3-hexenoic acid that confers resistance to DPP-4 cleavage. Pairs naturally with Semax's mechanism in metabolic / endocrine protocols.
Excellent tolerability. Mild nasal irritation possible. No dependence.
Lens-specific safety considerations for metabolic / endocrine use of Semax: Excellent tolerability. Mild nasal irritation possible. No dependence. Additional metabolic / endocrine monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Semax | ACTH-derived nootropic heptapeptide | CNS effect hours; plasma minutes | Metabolic |
| Semaglutide (GLP-1) | GLP-1 receptor agonist | ~7 days | The blockbuster GLP-1 receptor agonist with weekly dosing — engineered from native GLP-1 for protease resistance and albumin binding |
| Cagrilintide | Long-acting amylin analogue | ~7 days | A long-acting amylin analogue paired with semaglutide for weight loss results that exceed either drug alone |
| Tesamorelin | Stabilised GHRH analogue | ~30 min | An FDA-approved long-chain GHRH analogue used for HIV-associated lipodystrophy and notable for its consistent effect on visceral adipose reduction |
Will Semax affect my muscle mass during weight loss?
Pancreatitis or thyroid risk?
Will I regain weight after stopping Semax?
How does Semax affect glycemic control?
How long until I see results from Semax?
Is Semax safe during pregnancy or breastfeeding?
Start a Semax Protocol
Alukard provides physician-supervised metabolic protocols with GMP-certified Semax and GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
Get ProtocolQuick Facts
- Molecular weight
- 813 Da
- Sequence length
- 7 aa
- Half-life
- CNS effect hours; plasma minutes
- WADA
- Not on prohibited list
- FDA
- Unapproved (approved in Russia)
- Research
- Multi-decade Russian clinical use
Stack Partners
All metabolic / endocrine applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semax unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Metabolic / Endocrine Protocol for Semax
Alukard provides physician-supervised metabolic protocols with GMP-certified compounds with comprehensive metabolic and glycemic monitoring.
HIPAA Compliant · GMP Certified · Physician Supervised